8-K: Acreage Holdings Reports Q3 2024 Results, Highlights Ohio Launch and Canopy USA Acquisition Progress

Acreage Holdings announced its Q3 2024 financial results, noting a revenue of $39.6 million, the launch of non-medical sales in Ohio, and progress on its acquisition by Canopy USA.

Summary

• Acreage Holdings reported a consolidated revenue of $39.6 million for the third quarter of 2024, a decrease from $56.5 million in the same period last year.
• The company's gross margin was 35%, down from 38% in Q3 2023, and they experienced a net loss of $22.2 million.
• Adjusted EBITDA was $0.6 million, significantly lower than the $6.6 million reported in Q3 2023.
• Acreage launched non-medical cannabis sales in Ohio, which accounted for 38% of the state's revenue in Q3 2024.
• The company secured a capital infusion of approximately $8 million from an amended credit agreement.
• The acquisition by Canopy USA is expected to close no later than the first half of 2025.

Sentiment

Score: 4

Explanation: The document presents mixed results, with positive developments like the Ohio launch and capital infusion offset by significant declines in revenue, gross margin, and EBITDA. The overall tone is cautiously optimistic, but the financial performance is concerning.

Positives

• Acreage successfully launched non-medical cannabis sales in Ohio, capturing a significant portion of the state's revenue.
• The company secured a capital infusion of approximately $8 million, strengthening its financial position.
• Acreage is making progress on its acquisition by Canopy USA, expected to close in the first half of 2025.
• The company achieved strong wholesale penetration of its Superflux flower in Illinois.
• Acreage enhanced product inventory levels in key states, which is expected to improve sales.
• The company achieved record year-to-date wholesale revenue in New York in September.
• Acreage secured approval to relocate its Atlantic City dispensary to Collingswood, New Jersey.

Negatives

• Acreage's Q3 2024 revenue decreased to $39.6 million from $56.5 million in Q3 2023.
• The company's gross margin decreased to 35% from 38% in the same period last year.
• Acreage reported a net loss of $22.2 million for Q3 2024.
• Adjusted EBITDA significantly decreased to $0.6 million from $6.6 million in Q3 2023.
• The year-over-year revenue decrease was primarily due to liquidity constraints and competitive pressure.
• Decreases in gross profit and gross profit margin are related to increased costs for inventory inputs and price compression across the industry.

Risks

• The company faces risks related to changes in U.S. federal laws regarding cannabis.
• There are risks associated with the ability to receive necessary regulatory and shareholder approvals for the Canopy USA acquisition.
• The company's financial performance is subject to competitive pressures and market conditions.
• Acreage's ability to leverage the Canopy USA ecosystem is subject to the successful completion of the acquisition.
• The company faces risks related to compliance with extensive government regulations and the interpretation of various laws.
• There are risks related to the value and liquidity of the Floating Shares and the common shares of Canopy.

Future Outlook

Acreage anticipates improved sales and Adjusted EBITDA as it closes out 2024, driven by growth in core states and the Ohio market. The company is also actively seeking opportunities to collaborate with Jetty and Wana in anticipation of the Canopy USA acquisition.

Management Comments

• Dennis Curran, CEO of Acreage, stated that the company is focused on re-accelerating growth across core states and executing the launch of non-medical sales in Ohio.
• Curran also mentioned that the strengthened financial position will allow the company to pursue opportunities in maturing markets.
• He noted that the Ohio market presents an incredible growth opportunity.
• Curran stated that the acquisition by Canopy USA is advancing as planned and they are seeking opportunities to collaborate with Jetty and Wana.

Industry Context

This announcement comes as the cannabis industry continues to evolve, with increasing competition and regulatory changes. Acreage's focus on expanding into new markets like Ohio and its pending acquisition by Canopy USA reflect broader trends of consolidation and growth in the sector.

Comparison to Industry Standards

• Acreage's revenue decline of 30% year-over-year is concerning, as many multi-state operators (MSOs) are experiencing growth or smaller declines. For example, Curaleaf reported a 1% increase in revenue in their most recent quarter, while Trulieve saw a 10% decline.
• The gross margin of 35% is below the industry average, which is typically in the 40-50% range. Companies like Green Thumb Industries and Verano have consistently reported gross margins above 45%.
• Acreage's adjusted EBITDA of $0.6 million is significantly lower than peers. For example, Cresco Labs reported adjusted EBITDA of $47 million in their most recent quarter.
• The net loss of $22.2 million is also higher than many of its competitors, indicating potential challenges in profitability.
• The launch of non-medical sales in Ohio is a positive development, but its impact on overall financials remains to be seen. Other MSOs have seen significant revenue growth from new state launches, such as Trulieve in Pennsylvania and Verano in New Jersey.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in revenue and profitability.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers in Ohio will benefit from the launch of non-medical cannabis sales.
• Suppliers may be affected by the company's liquidity constraints and inventory management.
• Creditors may be impacted by the company's debt restructuring and financial performance.

Next Steps

• Acreage will continue to focus on re-accelerating growth in core states.
• The company will work to capitalize on the Ohio market.
• Acreage will seek opportunities to collaborate with Jetty and Wana.
• The company will work towards the closing of the Canopy USA acquisition in the first half of 2025.
• The Botanist Collingswood is expected to open for medical and adult-use sales in Q4 2024, subject to final regulatory approval.

Key Dates

Keywords

cannabis, Acreage Holdings, financial results, Q3 2024, Canopy USA, acquisition, Ohio, non-medical sales, EBITDA, revenue, gross margin, net loss, Superflux, The Botanist